<?xml version='1.0' encoding='utf-8'?>
<document id="25880724"><sentence text="Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects."><entity charOffset="40-50" id="DDI-PubMed.25880724.s1.e0" text="lanicemine" /><entity charOffset="52-59" id="DDI-PubMed.25880724.s1.e1" text="AZD6765" /><entity charOffset="88-97" id="DDI-PubMed.25880724.s1.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.25880724.s1.e0" e2="DDI-PubMed.25880724.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25880724.s1.e0" e2="DDI-PubMed.25880724.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25880724.s1.e0" e2="DDI-PubMed.25880724.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25880724.s1.e1" e2="DDI-PubMed.25880724.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25880724.s1.e1" e2="DDI-PubMed.25880724.s1.e2" /></sentence><sentence text="The objectives of the present study were to evaluate safety and tolerability as well as the effects of multiple doses of lanicemine on the pharmacokinetics of a CYP3A substrate, midazolam"><entity charOffset="121-131" id="DDI-PubMed.25880724.s2.e0" text="lanicemine" /><entity charOffset="178-187" id="DDI-PubMed.25880724.s2.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.25880724.s2.e0" e2="DDI-PubMed.25880724.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25880724.s2.e0" e2="DDI-PubMed.25880724.s2.e1" /></sentence><sentence text=" A total of 46 healthy volunteers were enrolled in the open-label, fixed-sequence, nonrandomized study" /><sentence text=" All volunteers received an oral dose of 5 mg of midazolam alone or after 6 days of 150 mg daily intravenous infusion of lanicemine"><entity charOffset="49-58" id="DDI-PubMed.25880724.s4.e0" text="midazolam" /><entity charOffset="121-131" id="DDI-PubMed.25880724.s4.e1" text="lanicemine" /><pair ddi="false" e1="DDI-PubMed.25880724.s4.e0" e2="DDI-PubMed.25880724.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25880724.s4.e0" e2="DDI-PubMed.25880724.s4.e1" /></sentence><sentence text=" Lanicemine reached a plasma Cmax of 1"><entity charOffset="1-11" id="DDI-PubMed.25880724.s5.e0" text="Lanicemine" /></sentence><sentence text="51 μg/mL after 150 mg daily dosing to steady state" /><sentence text=" The geometric mean CL, Vss, and t1/2 of lanicemine were 8"><entity charOffset="41-51" id="DDI-PubMed.25880724.s7.e0" text="lanicemine" /></sentence><sentence text="1 L/h, 122" /><sentence text="0 L, and 10" /><sentence text="4 hours, respectively" /><sentence text=" The geometric least-squares mean ratios and 90% confidence intervals for midazolam AUC0- ∞ , and Cmax were within the 80% to 125% limits when lanicemine plus midazolam treatment was compared with midazolam alone, demonstrating that daily dosing with 150 mg of lanicemine for 6 days had no effect on CYP3A activity"><entity charOffset="143-153" id="DDI-PubMed.25880724.s11.e0" text="lanicemine" /><entity charOffset="159-168" id="DDI-PubMed.25880724.s11.e1" text="midazolam" /><entity charOffset="197-206" id="DDI-PubMed.25880724.s11.e2" text="midazolam" /><entity charOffset="261-271" id="DDI-PubMed.25880724.s11.e3" text="lanicemine" /><pair ddi="false" e1="DDI-PubMed.25880724.s11.e0" e2="DDI-PubMed.25880724.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25880724.s11.e0" e2="DDI-PubMed.25880724.s11.e1" /><pair ddi="false" e1="DDI-PubMed.25880724.s11.e0" e2="DDI-PubMed.25880724.s11.e2" /><pair ddi="false" e1="DDI-PubMed.25880724.s11.e0" e2="DDI-PubMed.25880724.s11.e3" /><pair ddi="false" e1="DDI-PubMed.25880724.s11.e1" e2="DDI-PubMed.25880724.s11.e1" /><pair ddi="false" e1="DDI-PubMed.25880724.s11.e1" e2="DDI-PubMed.25880724.s11.e2" /><pair ddi="false" e1="DDI-PubMed.25880724.s11.e1" e2="DDI-PubMed.25880724.s11.e3" /><pair ddi="false" e1="DDI-PubMed.25880724.s11.e2" e2="DDI-PubMed.25880724.s11.e2" /><pair ddi="false" e1="DDI-PubMed.25880724.s11.e2" e2="DDI-PubMed.25880724.s11.e3" /></sentence><sentence text=" Comprehensive physiologically based pharmacokinetic modeling using in vitro and in silico findings also indicated lanicemine would have little impact on the pharmacokinetics of CYP3A substrate, such as midazolam"><entity charOffset="115-125" id="DDI-PubMed.25880724.s12.e0" text="lanicemine" /><entity charOffset="203-212" id="DDI-PubMed.25880724.s12.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.25880724.s12.e0" e2="DDI-PubMed.25880724.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25880724.s12.e0" e2="DDI-PubMed.25880724.s12.e1" /></sentence><sentence text=" In addition, lanicemine and midazolam administered alone or in combination were generally safe and well tolerated"><entity charOffset="14-24" id="DDI-PubMed.25880724.s13.e0" text="lanicemine" /><entity charOffset="29-38" id="DDI-PubMed.25880724.s13.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.25880724.s13.e0" e2="DDI-PubMed.25880724.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25880724.s13.e0" e2="DDI-PubMed.25880724.s13.e1" /></sentence><sentence text=" " /></document>